Ultragenyx Enters Duchenne Gene Therapy Space In $295m Deal With Solid Biosciences
Ultragenyx enters a competitive and complicated market, but the combination of its manufacturing platform with Solid’s transgene could provide an advantage.
Ultragenyx enters a competitive and complicated market, but the combination of its manufacturing platform with Solid’s transgene could provide an advantage.